US biotech company Biogen (Nasdaq: BIIB) has reported negative data from the Phase III trial of natalizumab, its blockbuster drug Tysabri, in secondary progressive multiple sclerosis.
The ASCEND trial evaluated the safety and efficacy of natalizumab to slow the accumulation of disability progression unrelated to relapse in secondary progressive multiple sclerosis patients, where the majority of study participants had EDSS scores of 6.0 to 6.5 which indicates a walking aid is required. They were non-relapsing for two years prior to enrolling in the study. The composite primary endpoint of the study evaluated the percentage of patients whose disability had progressed on one of more of three disability measurements comprising the composite endpoint. Natalizumab showed a significant effect on upper limb function unrelated to relapses.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews